LadRx Corporation · OTC:LADX
LadRx — Investor Presentation (September 2022)
20 slides from LadRx's investor presentation, September 2022
Slide 1: Corporate Overview September 2022
OTCQB:LADX CORPORATE OVERVIEW September 2022
Slide 2: LadRx Corporation Safe Harbor Statement
LadRx Corporation Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS “INTENDS,” “MAY,” “WILL,” “PLANS,” “EXPECTS,” “ANTICIPATES,” “PROJECTS,” “PREDICTS,” ESTIMATES,” “AIMS,” “BELIEVES,
Slide 3: Management and Board
Management and Board Board of Directors • Jennifer Simpson, PhD LadRx Chair of the Board. CEO of Panbela Therapeutics. Former CEO of Delcath, Oncology Stephen Snowdy, PhD Gilad Gordon, MD John Caloz Lead at Imclone, Product Director Oncology CEO R&D/Regulatory Consultant CFO Marketing at Ortho Biote
Slide 4: Cancer is a massive burden
Cancer is a massive burden In 2019, cancer claimed over 10 million lives worldwide1 Leading attributable causes (approx. half of cancers are attributable) are smoking, alcohol use, and high BMI 1 Cancer is the second leading cause of death in the US, behind heart disease2 Graphs Adapted from Center
Slide 5: Investment Highlights
Investment Highlights LadRx has developed elegant tumor targeting and release molecules called LADR that are based on LadRx is stage-diversified, with LADR-based drugs stretching small molecular entities (no complex antibodies or from registrational Phase 2 in pancreatic cancer to late pre- nanopart
Slide 6: LADR=Linker-Activated Drug Release
LADR=Linker-Activated Drug Release LADR-based drugs take advantage of circulating albumin as trojan horse: ➢ Major source of amino acids for tumors* ➢ Tumors use as carrier for metabolites, hormones, nutrients* ➢ Undergoes macropinocytosis* ➢ Accumulates in tumors due to EPR* ➢ Long half life* LADR:
Slide 7: Near-term potential milestone/royalty payments and a pipeline of next-gen candidates
Near-term potential milestone/royalty payments and a pipeline of additional next-gen candidates Doxorubicin reformulated with our LADR technology to improve therapeutic index. Licensed to Immunity Bio for up to $343M in potential milestones in addition to royalties on sales*. In Aldoxorubicin Regist
Slide 8: Aldoxorubicin: 1st Gen LADR-Based Drug Has Proven Higher Dosing with Improved Safety
Aldoxorubicin: 1st Gen LADR-Based Drug Has Proven Higher Dosing with Improved Safety in Human Trials Compared to Native Doxorubicin ➢ LADR allows for 3X higher dosing or more of doxorubicin When attached to LADR backbone, ➢ Aldoxorubicin crosses the Blood-Brain doxorubicin has Barrier been dosed in
Slide 9: Aldoxorubicin: 1st Gen LADR Partnered with ImmunityBio
Aldoxorubicin: 1st Gen LADR Partnered with ImmunityBio Trials have proven safety of higher dosing and efficacy Aldoxorubicin Preclinical Phase 1 Phase 2 Phase 3 Recurrent Glioblastoma P2A trial completed Immunity Bio moving into combo P2 Soft Tissue Sarcoma P3 showed safety/dosing, Immunity Bio cons
Slide 10: ImmunityBio Metastatic Pancreatic Cancer Study QUILT-88
ImmunityBio Metastatic Pancreatic Cancer Study QUILT-88 Pancreatic cancer will be diagnosed in 62k people in 2022 in the US, and will claim approximately 50K lives. Five-year survival is only 10%, and mean survival after 3 lines of therapy is 3 months 1 QUILT 88 study is a randomized, three cohort,
Slide 11: Next-Gen LADRs: LADR 7, 8, 9, 10
Next-Gen LADRs : LADR 7, 8, 9, 10 • High-throughput screening yielded four compounds selected for evaluation: • LADR 7: Auristatin-E with Ketone Linker • LADR 8: Auristatin-E with Ester Linker • LADR 9: Maytansine with Ketone Linker • LADR 10: Maytansine with Ester Linker • Auristatins and Maytansin
Slide 12: LADRs 7 and 8 in PDX/CDX cancer models: Melanoma
LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Melanoma
Slide 13: LADRs 7 and 8 in PDX/CDX cancer models: Ovarian
LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Ovarian
Slide 14: LADRs 7 and 8 in PDX/CDX cancer models: Non-Small Cell Lung Cancer
LADRs 7 and 8 are powerful anti-cancer drugs in multiple PDX/CDX cancer models: Non-Small Cell Lung Cancer
Slide 15: ...As are LADRs 9 and 10
.As are LADRs 9 and 10 w of the antitumor activity of maytansine and bumin-binding drugs in various human PDX and nograft tumor me glee rel els e. IEA bos 4 ABB 1 of b ils Flee z 3k & glelle/s lode ge glg/22 be eee 8 tle] eg mad a vPP EEE oem ARIE 25 & sls|s.3 cae [Ts 3 ame |e ora [ans | , ene ee oy
Slide 16: All Four LADR Candidates Meet Initial Development Criteria
All Four LADR Candidates Meet Initial Development Criteria Maytansinoid LADR™s (LADR- Auristatin LADR™s 9 and (LADR-7 and LADR-8) LADR-10) Selective Binding to Albumin and Stable in Plasma Payload Releases at pH 4 Robust Anti-Tumor Activity in Multiple Tumor Types Durable Responses Averaged 60‒90 Da
Slide 17: Next-gen LADR Progress Towards IND
Next-gen LADR Progress Towards IND ✓ Stability in plasma (mouse, rat, dog, monkey, human) ✓ pH-dependent release ✓ Rat and mouse MTD ✓ In-vitro efficacy ✓ In-vivo efficacy (small and large tumor PDX and CDX) ✓ Non-GLP rodent tox ✓ CMC GLP Mfg Run GLP rodent tox Non-GLP Non-Rodent MTD Time to IND 12-
Slide 18: Potential milestones and royalties from KemPharm for Arimoclomol
Potential milestones and royalties from KemPharm for Arimoclomol KemPharm KemPharm: Potential milestones Milestones and Royalties and royalties on arimoclomol Niemann-Pick disease (“NPC”) • Orphazyme filed an NDA with the FDA with Priority Review and received a Complete Response Letter on June 17, 2
Slide 19: Upcoming Potential Catalysts
Upcoming Potential Catalysts 2H22: Immunity Bio data on QUILT88 and meeting with FDA 2H22: Immunity Bio FDA meeting on Glioblastoma 1Q23: KemPharm submission to FDA for arimoclomol 2H22: Establish IND path for LADR 2H22-2H23: Updates on LADR advancement towards IND 1H24: First-in-human for LADR 7, 8
Slide 20: Summary
Summary LadRx has developed an efficient delivery platform for chemotherapeutic agents that takes advantage of the concentration of albumin in solid tumors. Being small molecules, the agents are easier/cheaper to manufacture than macromolecules, confer solubility, and crosses the blood-brain barrier